Gilead’s twice-yearly shot to prevent HIV succeeds in late-stage trial
Gilead's experimental twice-yearly medicine to prevent HIV was 100% effective in a late-stage trial, the company said Thursday.
Continue Reading https://www.cnbc.comGilead's experimental twice-yearly medicine to prevent HIV was 100% effective in a late-stage trial, the company said Thursday.
Continue Reading https://www.cnbc.com
Join the Discussion